On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.
Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."
Data provided by Nasdaq. Minimum 15 minutes delayed.
August 08, 2017
Nuvectra™ Reports Second Quarter 2017 Financial Results
Record Quarterly Algovita® Revenues, Increasing 62% Sequentially PLANO, Texas, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the second quarter ended June 30, 2017. Highlights Record consolidated revenues of $7.2 million, including total Algovita® sales of $5.5 million Completed FDA regulatory submission for full-body MRI-conditional approval for the Algovita SCS system On tr
July 28, 2017
Nuvectra to Present at the Wedbush PacGrow Healthcare Conference
PLANO, Texas, July 28, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Wedbush PacGrow Healthcare Conference in New York, NY. Management will also be available for one-on-one meetings at the conference. Event: Wedbush PacGrow Healthcare Conference Format: Present
The Ruth Group
|There are currently no events scheduled.|